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Abstract
Background: Chagas disease (CD), caused by the protozoan Trypanosoma cruzi, remains an important public health
issue in many Central and South American countries, as well as non-endemic areas with high rates of immigration
from these countries. Existing treatment options for CD are limited and often unsatisfactory. Moreover the lack of
post-treatment tests of cure limits the development of new drugs. To address this issue, we sought to identify
serum biomarkers following nifurtimox (Nfx) treatment that could be used as an early test of cure and/or markers of
a therapeutic response.
Methods: Human sera from Chagas patients pre- and post-treatment with Nfx (n = 37) were compared to samples
from healthy subjects (n = 37) using a range of proteomic and immunologic techniques. Biomarker peaks with the
best discriminatory power were further characterized.
Results: Using serum samples (n = 111), we validated the presence of five key biomarkers identified in our previous
study, namely human apolipoprotein A-I (APOA1) and specific fragments thereof and one fragment of human
fibronectin (FN1). In chagasic serum samples all biomarkers except full-length APOA1 were upregulated. These five
biomarkers returned to normal in 43% (16/37) of the patients treated with Nfx at three years after treatment.
Conclusions: The normalization of biomarker patterns strongly associated with CD suggests that these markers can
be used to identify patients in whom Nfx treatment is successful. We believe that these are the first biomarkers
predictive of cure in CD patients.
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Background
Chagas disease (CD) is an important public health con-
cern in Latin America, with an estimated eight million
persons chronically infected and a total cost due to loss
of productivity of ~$1.2 billion US/year [1] and $24.73
billion in health-care costs [2]. There are at least 41,000
new cases of CD due to vectorial transmission each year
[3]. Regardless of the route of transmission (eg: triatomine
insects, transfusion, mother-to-child, transplantation, or
contaminated foods), the majority of individuals infected
by T. cruzi remain asymptomatic for life [4]. However, 20-
30% will eventually suffer cardiovascular, gastrointestinal,
and/or neurological complications [1]. Once exclusively
an ‘exotic’ disease, CD has become a burden in many
non-endemic countries through migration, blood transfu-
sion, vertical transmission and organ transplantation. Ap-
proximately 300,000 chronically-infected individuals are
currently thought to be living in the United States [5].
Many European countries, Australia, Japan and Canada
are experiencing similar problems. For example, Spain
currently has >67,000 CD infected immigrants [6].
Despite the migration of large numbers of chronically-
infected CD patients in non-endemic countries, CD re-
mains a neglected disease. Since the introduction of Nfx
in 1965 and benznidazole in 1971, the development of
new drugs for CD has been negligible [7,8]. Parasito-
logical cure rates for benznidazole or Nfx vary with the
disease phase, dose, age, geographical origin and treat-
ment duration [9-12]. There is no consensus regarding
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optimal treatment duration which varies from 30 days
to 90 days depending on the tolerance to the drugs.
There is also no reliable test of cure that can be used
to monitor the effectiveness of treatment in chronic
CD patients [13].
Acute CD phase, which lasts for ~ ten weeks, is
relatively easy to diagnose by microscopy, polymerase
chain reaction (PCR), hemoculture or/and xenodiag-
noses [14]. However, the vast majority of CD cases
are not recognized and the disease enters the chronic
phase when these tests targeting parasite material in
the blood become unreliable due to the low and vari-
able levels of parasitemia. Therefore, negative results
using these tests cannot be used to either exclude in-
fection or confirm parasite clearance. During this
chronic stage, the diagnostic methods of choice are
serologic including indirect immunofluorescence (IFA),
indirect hemaglutination (IHA) or enzyme-linked immu-
nosorbent assays (ELISA) [15-18]. Unfortunately, these
serologic assays often yield inconclusive results [19] and
the Pan American Health Organization (PAHO) now
recommends the use of two different tests in parallel
[20]. Although these tests can remain positive for de-
cades after treatment, many investigators still rely on
them to assess cure [18,21-23]. In the last few years,
several studies focusing on biomarkers of cure in
chronic human disease have been proposed based on
hemostatic parameters [24], natriuretic peptides [25],
recombinant antigens [26], and lytic antibodies [27].
None of these approaches is particularly sensitive and
new biomarkers to monitor responses to CD treatment
are needed.
In recent years, mass spectrometric approaches have
seen increased use for a wide range of infectious dis-
eases [28-33]. We have used mass spectrometry to
identify biomarkers for Fasciola hepatica in sheep
[34], Taenia solium in pigs [35], and T. cruzi in chron-
ically infected patients [36]. The purpose of the
current study was to test our candidate T. cruzi bio-
markers in a cohort of adult patients treated with Nfx
and followed up after 3 years [21]. In this work, we not
only found the same biomarker pattern in the subjects
before treatment but confirmed their disappearance
in almost half of the subjects after treatment. Based on
these findings, we propose an algorithm to identify




All of the serum samples used in this study were col-
lected at the Geneva University Hospitals as part of a co-
hort study in 2008 described by Jackson et al. [37]. The
protocol of this study was approved by the Ethical Board
for Medical Research of the Geneva University Hospitals
(protocol 11–162). Written informed consent was ob-
tained from all participants.
Samples
Participants diagnosed with chronic CD received treat-
ment with Nfx and were called back for a follow-up
(FU) serum sample in 2011 [21]. A total of 37 paired CD
samples (pre- and post-Nfx or 2008-CD + and 2011-FU
respectively) and 37 samples from matched healthy con-
trol (HC) with similar epidemiologic risk were available
for study. The seronegative status of the HC was con-
firmed by two serological tests (i.e. BioMerieux Elisa
cruzi® and Biokit Bioelisa Chagas®). Patient characteris-
tics and the details of treatment have been described
elsewhere [21]. Written informed consent was obtained
from all participants. Sera were frozen (−20°C) within
1 hour of collection and stored in a bio-bank at the HUG.
Aliquot for each subject and time-point were sent to
the National Reference Center for Parasitology (Montreal,
QC) for the proteomics analysis.
ELISA and PCR assays have been described previously [21].
SELDI Analysis
Serum analysis was carried out as described by Ndao
et al. [30,36]. Briefly, 20 μl of each serum sample were
denatured and fractionated using 96-well filtration plates
in a series of ten minute incubations in buffers with de-
creasing pH. Serial washes yielded fractions 1–5 (pH 9,
7, 5, 4, and 3 respectively) with a last wash in organic
buffer (fraction 6). All six fractions were bound on both
CM10 (weak cationic-exchange) and IMAC30 (immobi-
lized metal) ProteinChip arrays (Bio-Rad Laboratories,
Hercules, CA) as described [30,36]. Arrays were then
air-dried and 1 μl of energy-absorbing matrix (sinapinic
acid, Bio-Rad) was added twice to each spot. The surface
was allowed to air dry between each application. Arrays
were analyzed in a ProteinChip system reader (PCS-
4000) using the ProteinChip Data Manager Software
version 3.5 (Bio-Rad). Each spot was read at low and
high-energy laser intensities. Spectra were calibrated and
normalized as previously described [36].
Data was analyzed using ProteinChip Data Manager
Software as described in detail previously. P values for
differences in peak intensities between the three groups
(2008-CD+, 2011-FU and HC) for each cluster were gener-
ated using the Mann–Whitney U test. Diagnostic perform-
ance was assessed by determining the area under the
receiver-operating characteristic (ROC) curve for each po-
tential biomarker. The Biomarker Patterns Software version
5.0.2 (Bio-Rad), a classification method, was then used to
identify peaks with the greatest contribution to discrimin-
ation between groups (HC, 2008-CD+ and 2011-FU).
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Cross-validation of SELDI results and biomarker identity
confirmation
Neo-epitope antisera against human APOA1 and
FN1 fragments
Rabbit anti-peptide sera were generated against the pre-
dicted neo-termini of the 24.7 kDa fragment of APOA1
(PALEDL: amino acids 209–214) and the 28.9 kDa frag-
ment of FN1 (GPFTDV: amino acids 253–258) were con-
jugated to immunogenic KLH (CanPeptide, Pointe-Claire,
QC) and sent to Cocalico Biologicals Inc (Reamstown,
PA) for rabbit immunization and antiserum production.
These antisera recognized the CD-associated fragments
but not the native forms.
Immunoblot confirmation of biomarkers presence in
serum samples
Individual and pooled serum samples from HC and
paired 2008-CD + and 2011-FU samples were separated
in 4-12% Novex Bis-Tris Midi gradient gels (Life Technolo-
gies, Carlsbad, CA) under reducing conditions. Separated
proteins were transferred to nitrocellulose membranes by
iBlot dry transfer (Life Technologies). Transfer efficiency
was assessed by Ponceau Red. Membranes were incubated
overnight at 4°C with either the rabbit anti-APOA1(24)
serum at 1:500 or the rabbit anti-FN1(28) serum at 1:1,000
dilution followed by incubation with HRP-conjugated
anti-rabbit IgG at a 1:100,000 dilution (GE Healthcare
Life Sciences, Uppsala, Sweden). The membranes were
incubated in SuperSignal West Pico detection (Pierce,
Rockford, IL) and exposed to autoradiography.
Validation of SELDI results by ZOOM fractionation
Pools of HC (n = 4) and 2008-CD + (n = 4) samples were
fractionated using the ZOOM IEF Fractionator (Life
Technologies). The pools (20 μl) were solubilized, de-
natured and alkylated in a final concentration of 1X IEF
Denaturant, 1X protease inhibitor cocktail (EMD4 Bio-
sciences, Calbiochem, Gibbstown, NJ), 40 mM DTT, 5 mM
EDTA, 10 mM Tris base and ~50% N,N-dimethylacryla-
mide. The samples were diluted to a final volume of 3.5 ml
with 1.1X IEF Denaturant according to the manufacturer’s
protocol. Five fractions of varying pH were collected:
pH 10-9.1, pH 9.1-7, pH 7-5.4, pH 5.4-4.6, and pH 4.6-3.
Based on the SELDI results, ZOOM fractions pH ranges
5.4-10 were most likely to contain the APOA1 and FN1
fragments. Fractions were separated on Mini-PROTEAN
4-15% TGX gradient gels (Bio-Rad) for immunoblot
assessment and in-gel trypsin digestion. Immunoblots
were performed as described above.
In-gel trypsin digestion
The gels were stained with Bio-safe Coomassie stain (Bio-
Rad). Gel bands of interest were excised and transferred
to Eppendorf tubes for trypsin digestion using proteomics
grade recombinant trypsin according to the manufacturer
protocol (Roche, Penzberg, Germany). A gel piece from
an empty corner of the pre-cast gel was simultaneously
processed for use as a blank. The blank sample was used
to generate an exclusion list of common contaminating
peaks from the gel, the trypsin and the α-cyano-4-hydro-
xycinnamic acid (CHCA) matrix used during spotting.
The samples were desalted using ZipTips C18 (Millipore,
Billerica, MA) following the manufacturer’s protocol.
Samples were eluted with 4 μl matrix solution (10 mg/
ml CHCA in 50% ACN and 0.1% TFA) and spotted
directly on a 384-well Opti-TOF MALDI plate (AB
Sciex, Framingham, MA) in 1 μl aliquots and allowed
to air-dry at room temperature.
MALDI MS-MS identification of biomarkers
MALDI data was acquired using a 4800 Plus MALDI
TOF/TOF Analyzer (AB Sciex) with the 4000 Series Ex-
plorer software version 3.5.3. The instrument was cali-
brated using the AB Sciex Mass Standards Kit. Data was
first acquired in the MS positive-ion reflector mode at a
fixed laser energy of 3200. A reflector interpretation
method was created to run the MS-MS 1kv positive ac-
quisition method in batch mode on all spots. The MS-
MS was performed at 4200 fixed laser intensity on the
50 strongest precursor peaks discovered during the re-
flector mode acquisition. The exclusion list of common
CHCA, trypsin and gel contaminant peaks was also in-
cluded as a parameter in the interpretation method to
improve for the selection of protein-specific precursor
peaks. MS-MS data was analyzed with ProteinPilot soft-
ware version 4.0.8 (AB Sciex) based on the paragon algo-
rithm. MS-MS data was searched against the most
recent Homo sapiens protein database from Uniprot
(Swiss-Prot/TrEMBL annotated protein sequences).
Results
Identification of serum markers from chagasic patients
using SELDI
The 111 sera studied yielded a total of 2664 spectra.
From the list of 18 candidate biomarkers identified in
our previous work [36], 15 were also found in the
current study (Table 1). All showed statistically signifi-
cant differences (p < 0.05) in peak intensity between the
2008-CD + samples and HC samples. All but two (5.4
and 28.1 kDa) were up-regulated in CD patients (2008-
CD+/HC fold ratio). When the 2008-CD + and 2011-FU
were compared, all but one of these 15 candidate bio-
markers (5.4 kDa) demonstrated statistically significant
intensity shifts towards the normal values of the HC
group. Nine of the 15 biomarkers were no longer signifi-
cantly different between HC and 2011-FU samples (7.8,
9.3, 10.1, 12.7, 13.6, 15.2, 16.3, 24.7 and 28.1 kDa: p-values
all > 0.05), strongly suggesting the ‘normalization’ of these
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biomarkers after treatment with Nfx (Table 1). The cluster
plots (Figure 1) show a visual representation of peak in-
tensity levels in the HC, 2008-CD + and 2011-FU groups
for five of the best potential biomarkers. Based upon our
previous work, most of these biomarkers are of host origin
[36]. In particular, the 9.3, 13.6 and 24.7 kDa peaks were
identified as human APOA1 fragments and the 28.1 kDa
peak is the mature form of APOA1. Another peak of
interest is the 28.9 kDa protein previously identified as a
fragment of FN1 [36].
Immunoblot confirmation of selected markers in sera
The specificity of the antisera for the targeted fragments is
well demonstrated in Figure 2A in which the anti-APOA1
(24) detects a single band at ~27 kDa that corresponds to
the 6xHis-tagged recombinant APOA1 24.7 kDa fragment
(lane R). No band is detected in the lane loaded with the
native 28.1 kDa native form of APOA1 (lane FL) pur-
chased from Sigma. Similarly, the anti-FN1(28) detects a
single band corresponding to the 6xHis-FLAG recombin-
ant FN1 28.9 kDa fragment (Figure 2C, lane R) but not
native FN1 (~210 and ~220 kDa) (Figure 2C, lane FL) was
not detected by the anti-FN1(28) (high molecular range
data not shown). Staining with Ponceau Red confirmed
successful transfer of the full-length proteins to the nitro-
cellulose (data not shown). Probing individual and pooled
samples demonstrated up-regulation of both the 24.7 kDa
APOA1 (Figure 2A,B) and 28.9 kDa FN1 (Figure 2C,D)
fragments in Chagas patients (2008-CD + lanes) com-
pared to sera from healthy individuals (HC lanes). Band
intensities are much reduced three years after Nfx treat-
ment (2011-FU lanes). The immunoblots results were
consistent with the patterns observed on both the cluster
plots (Figure 1) and the mean signal intensities (Table 1).
Immunoblots analysis of ZOOM fractions 2 and 3 con-
firmed the presence of both the 24.7 kDa APOA1 and the
28.9 kDa FN1 fragments (Figure 3A,B).
MALDI MS-MS analysis of ZOOM fractions
Aliquots of ZOOM fractions 2 and 3 were separated by
gel electrophoresis and stained (Figure 3A,B). Gel bands
at ~25 kDa and ~29 kDa were excised and subjected to
in-gel trypsin digestion. The 50 peaks (Figures 4A and
5B) with the highest intensity were subjected to MS-MS
sequencing which confirmed the presence of human
APOA1 (Uniprot accession#: APOA1_HUMAN) in
ZOOM fraction 3 with eight peptides covering 47.7%
of the mature protein (Figure 4B,C). The leucine residue
at position 214 (highlighted in black bold, Figure 4C) is
where we believe mature APOA1 is cleaved by cruzi-
pain to give rise to the 24.7 kDa APOA1 fragment [36].
Since no precursor peptide was identified and se-
quenced beyond this leucine residue, these data are
consistent with the immunoblot results suggesting the
presence of the 24.7 kDa APOA1 fragment rather than
the full-length protein in ZOOM fraction 3. Similarly





P value (CD + vs HC)
AUC for ROC curve
(fold CD/HC)
P value (FU vs HC)
AUC for ROC curve
(fold FU/HC)
P value (CD + vs FU)
AUC for ROC curve
(fold CD/FU)
Mean signal intensity ± SEM
HC CD+ FU
(n = 37) (n = 37) (n = 37)
3.7 F1 CM10 0.0001, 1.0 (+4.2) 0.0001, 0.88 (+2.3) 0.0011, 0.82 (+1.8) 1.54 ± 0.11 6.46 ± 0.64 3.60 ± 0.45
4.4 F1 IMAC; F1,5 CM10 0.0001, 1.0 (+3.7) 0.0159, 0.69 (+1.7) 0.0001, 0.91 (+2.2) 7.66 ± 0.53 28.35 ± 1.74 12.84 ± 1.91
5.4a F1, 3 CM10 0.0001, 1.0 (−0.3) 0.0001, 0.99 (−0.2) 0.2427, 0.65 (+1.2) 3.51 ± 0.31 0.90 ± 0.07 0.75 ± 0.10
6.6 F3,5 CM10 0.0001, 1.0 (+3.4) 0.0001, 0.91 (+2.5) 0.0028, 0.79 (+1.4) 3.65 ± 0.26 12.45 ± 0.62 8.96 ± 0.89
7.8 F1,3 CM10 0.0001, 0.97 (+3.9) 0.3405, 0.55 (+1.2) 0.0005, 0.91 (+3.15) 0.55 ± 0.07 2.14 ± 0.35 0.68 ± 0.12
9.3 F1,4 IMAC; F1,3 CM10 0.0001, 0.92 (+1.7) 0.9456, 0.51 (+1.0) 0.0001, 0.87 (+1.7) 2.74 ± 0.26 4.76 ± 0.24 2.77 ± 0.31
10.1 F1,3,4,6 IMAC; F1 CM10 0.0001, 0.88 (+2.0) 0.3622, 0.56 (−0.9) 0.0001, 0.96 (+2.3) 15.27 ± 1.80 30.48 ± 2.92 13.13 ± 1.42
12.7 F2,5 IMAC; F1,5,6 CM10 0.0003, 0.80 (+2.0) 0.5879, 0.53 (+1.2) 0.0129, 0.73 (+1.7) 2.59 ± 0.41 5.27 ± 0.55 3.02 ± 0.68
13.6 F1 IMAC; F1 CM10 0.0001, 0.96 (+2.3) 0.2220, 0.59 (+1.2) 0.0001, 0.86 (+1.8) 4.43 ± 0.51 10.07 ± 0.62 5.50 ± 0.71
15.2 F4,5 IMAC; F1,3,6 CM10 0.0001, 1.0 (+2.9) 0.6538, 0.51 (+1.1) 0.0001, 0.96 (+2.7) 5.62 ± 0.51 16.46 ± 1.33 6.04 ± 0.75
16.3 F4 IMAC; F3,6 CM10 0.0001, 0.95 (+3.1) 0.4349, 0.58 (+1.2) 0.0001, 0.94 (+2.6) 1.77 ± 0.30 5.48 ± 0.48 2.10 ± 0.28
24.7 F2 IMAC 0.0001, 0.84 (+1.8) 0.6429, 0.51 (−0.9) 0.0001, 0.85 (+1.9) 1.48 ± 0.16 2.61 ± 0.19 1.37 ± 0.18
28.1a F1,3 CM10 0.0001, 0.96 (−0.8) 0.3598, 0.56 (−1.0) 0.0032, 0.79 (−0.8) 28.43 ± 0.63 21.66 ± 1.07 27.06 ± 1.23
28.9 F1 IMAC 0.0001, 0.98 (+3.5) 0.0182, 0.66 (+1.9) 0.0006, 0.80 (+1.9) 0.46 ± 0.07 1.61 ± 0.13 0.86 ± 0.15
75.4 F1 CM10 0.0001, 1.0 (+3.0) 0.0005, 0.83 (+1.9) 0.0001, 0.96 (+1.6) 1.18 ± 0.15 3.53 ± 0.09 2.25 ± 0.23
a Downregulated protein in CD-positive subjects.
Mass (m/z), mean intensities, and AUC’s for selected differentially expressed peptides/proteins between HC, 2008-CD + and 2011-FU sera samples.
An area under the curve (AUC) of 1 suggests good diagnostic power, while AUC values that approach 0.5 indicate little diagnostic potential. HC: Healthy control;
CD: Chagas disease; FU: follow-up.
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human FN1 (Uniprot accession#: F8W7G7_HUMAN)
was identified from MS-MS data in ZOOM fraction 2
with >14 peptides covering 48.3% of the N-terminal
domain of FN1 (Figure 5B,C). In this case, cruzipain is
presumed to cleave full-length FN1 at the valine residue
in position 258 (highlighted in black bold, Figure 5C).
Again no precursor peptide was identified and sequenced
beyond this valine residue.
Discrimination between groups using the biomarker
pattern software
When healthy controls and 2008-CD + samples were
compared, the best discriminatory peaks identified by
the BPS were 28.9, 28.1, 13.6, 9.3 and 24.7 kDa (Figure 6).
These biomarkers corresponded to the 28. 9 kDa FN1
fragment, full-length APOA1 and three of the APOA1
fragments respectively. Taking this into account and as-
suming that the pattern of biomarkers is strong enough
to discriminate between a Chagas sample and a healthy
sample, a patient could be considered cured when the
identified sera markers have the same profile as that
found in healthy volunteers i.e. FN1 fragment (28.9 kDa)
and all APOA1 truncations (9.3, 13.6 and 24.7 kDa) are
down-regulated and full-length APOA1 (28.1 kDa) is
up-regulated. We therefore applied the same algorithm
to classify the 2011-FU samples according to the algo-
rithm used to discriminate between healthy controls and
Chagas patients in order to define whether a patient can
be classified as cured or not.
Table 2 summarizes the patterns of selected bio-
markers in follow-up samples from patients treated with
Nfx. As described previously, all 37 subjects tested posi-
tive by ELISA, making it difficult to draw any conclusion
about treatment efficacy [21]. One patient treated for
60 days with Nfx was found to be still Chagas positive as
assessed by real-time PCR [21]. The biomarker pattern
found for this patient matches that of a Chagas patient
(three APOA1 and one FN1 fragments up-regulated and
Figure 1 Cluster plots of selected differentially expressed biomarkers. Cluster plots demonstrate the expression pattern of selected
biomarkers between the different groups (HC = healthy controls; 2008-CD + = chagasic samples; 2011-FU = follow-up samples from patients
having received treatment with Nfx). Biomarker expression levels in samples treated with Nfx (2011-FU) all return to the levels observed in healthy
controls (HC). All biomarkers, except for one, are upregulated during disease (2008-CD+). The downregulated biomarker was previously identified
as native human APOA1 (28.1 kDa); the 9.3, 13.6 and 24.7 kDa biomarkers were identified as fragments of human APOA1; and the 28.9 kDa biomarker
as a fragment of human FN1.
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Figure 2 Immunoblot analysis of sera using rabbit anti-neoepitope antisera. Immunoblot analysis of sera from healthy controls (HC), 2008
chagasic samples (2008-CD+) and 2011 follow-up samples (2011-FU) probed with specific rabbit neo-epitope antisera. (A) Analysis of pooled sera
and (B) individual sera with anti-APOA1(24) demonstrates the upregulation of the 24.7 kDa APOA1 fragment in 2008-CD + samples and its
down-regulation back to healthy controls level in the 2011-FU samples. The specificity of the rabbit anti-APOA1(24) serum for the 24.7 kDa
fragment is demonstrated by its inability to detect native full-length APOA1 (~28.1 kDa) (FL) while reacting with a 6xHis recombinant of the 24.7
APOA1 fragment (~27.4 kDa) (R). (C) Analysis of pooled and (D) individual sera with rabbit anti-FN1(28) serum demonstrates the up-regulation of
the 28.9 kDa FN1 fragment in 2008-CD + samples and its down-regulation in the 2011-FU samples almost back to the levels observed in healthy
controls. The specificity of the rabbit anti-FN1(28) serum for the 28.9 kDa fragment is demonstrated by its inability to detect native full-length FN1
(~210 and ~220 kDa) (FL) while reacting with a FLAG-6xHis recombinant of the 28.9 FN1 fragment (~35 kDa) (R).
Figure 3 Immunoblot analysis of ZOOM fractions using specific anti-neoepitope antisera and Coomassie gel used for in-gel trypsin
digestion. Coomassie, Ponceau Red and Immunoblot analysis of pooled sera fractionated by ZOOM IEF Fractionation validate SELDI results. (A)
ZOOM fractions 2 and 3 probed with anti-APOA1(24) rabbit serum confirms the presence and up-regulation of the 24.7 kDa APOA1 biomarker in
2008-CD + samples vs healthy control (HC) samples especially in fraction 3 (pH range 5.4-7). (B) ZOOM fractions 1 and 2 probed with anti-FN1(28)
confirms the presence and up-regulation of the 28.9 kDa FN1 biomarker in 2008-CD + vs HC samples in fraction 2 (pH range 7-9.1).
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full-length APOA1 down-regulated). Similar patterns
should identify treated but not cured patients. Among
the patients that received Nfx treatment for less than
40 days, nine out of ten could be classified as Chagas pa-
tients, eight of those displaying exactly the same pattern
as the only patient positive by real-time PCR. Interest-
ingly, one patient that followed the treatment for 21 days
was classified as cured. Of the full cohort of 37 patients,
the overall cure rate was 43.2%, with 15 of the 27 patients
(55.6%) who received treatment for 47 to 60 days (25 of
whom completed the full 60 days) classified as healthy
therefore cured, and ten as Chagas patients not cured.
Discussion
The identification of T. cruzi by xenodiagnosis, hemocul-
ture, microscopy or DNA based assays provides a defini-
tive diagnosis for Chagas disease and can be routinely
used to accurately diagnose the disease in the acute phase.
However, during the indeterminate or chronic phase these
tools are unreliable and a negative result may not mean
lack of infection or parasitic cure of an infected patient,
with serological methods being more informative.
Once a positive diagnosis has been confirmed, there
are only two drugs available for treatment (Nfx and
benznidazole) [38]. These drugs have significant side-
effects [39] and their efficacy is controversial as there is
currently no way to measure cure rates without decades
of follow-up. There is consequently a lack of consensus on
treatment duration throughout the community studying
Chagas disease [40], and policy decisions and recommen-
dations cannot be made. There is an urgent need for a re-
liable test that can determine cure in treated patients and
measure treatment efficacy for a drug [41].
In our previous study we assessed cure in a cohort of
adult patients treated with Nfx and followed up after
three years by various diagnostic tools. Our results
Figure 4 MALDI identification of human apolipoprotein A-I. MALDI MS-MS data confirms the identification of the 24.7 kDa biomarker to be
a fragment of human APOA1. (A) MS Reflector Positive spectrum obtained from the in-gel trypsin digestion of the ~25 kDa band cut out from
fraction 3 shows the precursor peaks generated by trypsin. (B) ProteinPilot MS-MS data shows that 8 peptides were sequenced and matched to
human APOA1 with more than 95% confidence. (C) MS-MS sequence coverage. Peptides sequenced with more than 95% confidence (green) or
less 95% confidence (red) together covered 47.7% of the full-length APOA1 human protein sequence.
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demonstrated the inadequacy of conventional sero-
logical tests for assessing cure in patients. In the cohort,
97.3% had results that could either indicate treatment
failure or persistent humoral response despite having
undergone treatment. On the other hand, the same samples
all tested negative by conventional PCR and all but one
tested negative by RT-PCR. These results reinforced the
need for a robust and rapid test to assess treatment efficacy
with certainty.
Research on the discovery and use of new antigens for
diagnosis is on-going [42-44], but new diagnostic tech-
niques such as proteomics [36] and flow cytometry [45]
are also being investigated. In this study, we looked at
the effect of Nfx in Chagas patients by using proteomics
on samples from the same cohort of adults described in
our previous study. We targeted our research on key
biomarkers previously identified in our laboratories for
diagnostic purpose [36] with a two-fold objective: assess
whether specific biomarkers could be discriminative
enough and help in defining cure in patients on the one
hand and could be used as potential antigens for further
development of new test of cure on the other hand.
Using SELDI, we successfully identified the majority of
the key biomarkers discovered in our previous study
Figure 5 MALDI identification of human fibronectin. MALDI MS-MS data confirms the identification of the 28.9 kDa biomarker to be a fragment
of human FN1. (A) MS Reflector Positive spectrum obtained from the in-gel trypsin digestion of the ~30 kDa band cut out from fraction 2 shows
the precursor peaks generated by trypsin. (B) ProteinPilot MS-MS data shows that 14 peptides were sequenced and matched to human FN1 with
more than 95% confidence. (C) MS-MS sequence coverage. Peptides sequenced with more than 95% confidence (green) covered 48.3% of the
amino-terminal domain of the FN1 human protein sequence.
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[36] in the three test groups (healthy, infected and Nfx-
treated follow-up samples), focusing on key biomarkers
(mature human APOA1 (28.1 kDa); fragments of human
APOA1 (24.7, 13.6 and 9.3 kDa); and a fragment of hu-
man FN1 (28.9 kDa). The pattern of these biomarkers
between healthy and diseased samples was consistent
with those seen in our previous study, i.e. all truncated
fragments were up-regulated during disease compared
to healthy controls whereas full-length APOA1 was
downregulated during disease compared to healthy con-
trols. These results, based on samples from Bolivian pa-
tients, confirm those previously seen with Venezuelan
patient samples and demonstrate the reproducibility of
SELDI technology across populations from South Amer-
ica [36]. Cluster plots showed that the levels of these
biomarkers in follow-up samples of patients treated with
Nfx returned to levels similar to those seen in healthy
controls.
Seroconversion is currently the only surrogate marker
of cure for Chagas disease. Given that all patients in this
cohort were seropositive at the three year follow-up, we
could not make any correlation with seroconversion.
Our five chosen biomarkers were shown to achieve up
to 100% sensitivity and 98% specificity for CD, enabling
the classification of follow-up samples as coming from
healthy (or cured) or Chagas subjects. The results indi-
cated that Nfx had no effect in 56.2% (n = 21/37) of the
patients, one of whom was known to be still infected
with T. cruzi (positive RT-PCR).
Nfx treatment length was found to be important, as
nine out ten patients who pursued treatment for less
than 40 days were still classified as Chagas disease pa-
tients. Of the 27 patients who followed Nfx treatment
for more than 40 days, 25 of whom complied with the
full 60 days of treatment, 15 (55.6%) were classified as
healthy and would be considered as cured.
Taken together these results suggest that these bio-
markers might be useful in assessing treatment efficacy
in chagasic patients and could lead to the development
of a test of cure. Moreover, their evaluation in animal
models of Chagas disease could lead to improvements in
the predictability of these models and their translation
to the human disease during the drug discovery and de-
velopment process.
Although very encouraging, it is important to point
out that our study has limitations, and further studies
will be needed to establish the real potential of these
markers for their use as test of cure and assessment of
treatment efficacy for Chagas disease. We were unable
to correlate the biomarkers data with seroconversion,
the only surrogate for Chagas disease, and had to rely on
the discriminatory power of an algorithm using these
markers. Since seroconversion in children is much quicker
than in adults (1–2 years and decade(s) respectively), a
Figure 6 Biomarker patterns software based on CART analysis used to generate candidate diagnostic algorithms between the HC and
2008-CD + groups. Biomarker patterns software based on CART (Classification and Regression Tree) analysis was used to generate candidate
diagnostic algorithms. Decision tree classifications using healthy controls (HC) vs 2008 chagasic samples (CD+) are shown. Biomarkers establishing
the splitting rules are 9.3, 13.6, 24.7, 28.1, 28.9 kDa. Cases that follow the rule are placed in the left daughter node (YES), and samples that do not
follow the rule are placed in the right daughter node (NO).
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follow-up study with sera samples from treated children
would confirm a correlation between these biomarkers
and seroconversion, and therefore cure. Indeed, access to
samples of adults treated for Chagas disease with follow-
up samples for decades is very limited. We also did not
have serum samples corresponding to End of Treatment
(EoT) for analysis. Indeed, being able to establish cure and
perform counseling at the end of treatment would already
be a major breakthrough, and would eliminate the need
for a long follow-up. In addition, it may be possible to
Table 2 Expression patterns of selected biomarkers in 2011 follow-up samples compared to 2008 Chagasic patients



















60 54 ↓ ↓ ↓ ↑ ↓ 0.62 0.62 + - - C
60 56 ↓ ↓ ↓ ↑ ↓ 2.53 2.02 + - - C
60 57 ↓ ↓ ↓ ↑ ↓ 0.41 0.50 + - - C
60 59 ↓ ↑ ↓ ↑ ↓ 2.37 2.17 + - - C
60 60 ↑ ↑ ↑ ↓ ↑ 2.80 2.57 + - - NC
60 62 ↓ ↓ ↑ ↑ ↓ 2.55 2.11 + - - NC
60 65 ↓ ↓ ↑ ↑ ↓ 0.79 0.61 + - - NC
60 68 ↓ ↑ ↓ ↓ ↓ 1.88 1.53 + - - NC
60 69 ↓ ↓ ↑ ↑ ↓ 1.84 1.75 + - - NC
60 70 ↓ ↑ ↑ ↑ ↓ 1.11 1.23 + - - NC
60 71 ↑ ↑ ↑ ↓ ↑ 1.64 1.19 + - + NC
60 72 ↓ ↓ ↓ ↑ ↓ 1.47 1.67 + - - C
60 77 ↓ ↑ ↓ ↑ ↓ 2.16 1.58 + - - C
60 84 ↓ ↑ ↓ ↑ ↓ 2.94 2.49 + - - C
60 85 ↓ ↑ ↑ ↓ ↓ 1.76 2.11 + - - NC
60 86 ↑ ↓ ↓ ↑ ↓ 2.18 2.25 + - - NC
60 87 ↓ ↓ ↓ ↑ ↓ 1.95 1.89 + - - C
60 91 ↓ ↓ ↑ ↑ ↓ 2.16 1.83 + - - NC
60 94 ↓ ↓ ↓ ↑ ↓ 2.07 1.93 + - - C
60 97 ↓ ↓ ↑ ↑ ↓ 2.26 1.85 + - - NC
60 99 ↓ ↑ ↓ ↑ ↓ 1.69 1.25 + - - C
60 100 ↓ ↓ ↓ ↑ ↓ 2.17 1.79 + - - C
60 102 ↓ ↓ ↓ ↑ ↓ 2.61 1.31 + - - C
60 103 ↑ ↓ ↑ ↓ ↑ 2.56 2.28 + - - NC
60 104 ↓ ↓ ↓ ↑ ↓ 2.78 1.97 + - - C
58 64 ↓ ↓ ↓ ↑ ↑ 2.55 2.27 + - - C
47 67 ↓ ↓ ↓ ↑ ↓ 1.83 1.90 + - - C
31 58 ↑ ↑ ↑ ↓ ↑ 2.28 1.91 + - - NC
21 80 ↓ ↑ ↓ ↑ ↓ 2.42 1.78 + - - C
21 81 ↑ ↑ ↑ ↓ ↑ 2.16 1.70 + - - NC
21 88 ↑ ↑ ↑ ↓ ↑ 2.02 1.64 + - - NC
19 96 ↑ ↑ ↑ ↓ ↑ 1.99 2.42 + - - NC
16 90 ↓ ↑ ↑ ↓ ↓ 1.44 1.02 + - - NC
14 95 ↑ ↑ ↑ ↓ ↑ 1.13 2.24 + - - NC
10 66 ↑ ↑ ↑ ↓ ↑ 2.35 1.92 + - - NC
10 73 ↑ ↑ ↑ ↓ ↑ 2.21 2.00 + - - NC
2 55 ↑ ↑ ↑ ↓ ↑ 2.65 2.82 + - - NC
ELISA cut-off: 0.4.
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establish if down-regulation of key biomarkers is dir-
ectly linked to the absence of cruzipain (cruzipain cleav-
age sites have been identified in the APOA1 and FN1,
data not shown).
Finally, access to and analysis of samples originating
from larger cohorts of patients treated with other drugs
(e.g. Benznidazole) would be very useful and could fur-
ther validate our findings.
Conclusions
There is a lack of reliable tests for assessment of cure
following treatment in chronic Chagas disease patients.
In this study we identified a biomarker pattern strongly
associated with CD. Using an algorithm, we showed that
Nfx-treated patients that have the same biomarker pro-
file/pattern as healthy controls were classified as cured.
Further studies using samples from chagasic children
would be useful to address the correlation between these
biomarkers and seroconversion.
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